Episode Summary
Executive Summary: Peter Attia and Dr. Lloyd Klickstein unpack how drugs are actually discovered, developed, and approved, using Bimagrumab (BEMA) as a case study. They cover unmet-need-driven target selection, the tradeoffs between small molecules and biologics, patents and GMP manufacturing, preclinical/clinical trial design, and why BEMA became a major obesity/muscle-preservation asset. The episode also broadens to preventive medicine, mTOR inhibition, and a new cancer-prevention company.
Main Topics: How new drugs are discovered from unmet need (Priority: 5/5): Klickstein explains that drug discovery should start with patients and unmet clinical indications, then move to target selection, target validation, and a practical development strategy that balances novelty with feasibility. Drug classes, biologics, and why format matters (Priority: 4/5): The conversation distinguishes small molecules, biologics, gene therapies, and devices, emphasizing that disease biology and delivery constraints often dictate which modality is most viable. Patents, exclusivity, trade secrets, and GMP (Priority: 4/5): They discuss how patents protect investment, why companies patent composition/formulation/manufacturing details, and why GMP-quality manufacturing is essential for safe, reproducible medicines. Bimagrumab discovery and preclinical development (Priority: 5/5): Klickstein walks through the myostatin/activin receptor biology, antibody screening, rodent and primate testing, toxicology, and the rationale for choosing a receptor-targeting biologic for muscle preservation. Clinical development, endpoints, and the obesity pivot (Priority: 5/5): The episode details phase-one and phase-two strategy, selection of healthy vs affected participants, difficulties measuring falls and strength, and how BEMA moved into obesity and combination studies with GLP-1 drugs. Results, limitations, and commercial strategy (Priority: 4/5): BEMA reliably increased muscle mass and reduced fat mass, but strength gains were modest; the company then pivoted, was acquired by Eli Lilly, and the discussion highlights how endpoint choices shape the business. Future directions: preventive medicine, mTOR, and cancer prevention (Priority: 3/5): Klickstein argues the future of medicine will be more prevention-focused and describes a new company aiming to prevent cancers by gently activating a stress-response pathway; he also comments on selective mTOR inhibition.
Key Arguments: Drug discovery should begin with a real unmet patient need, not just an interesting molecule. Incremental improvements are safer, but the biggest societal value often comes from creating entirely new indications or treatment pathways. Biologics are often better than small molecules when the target interaction requires very high affinity and specificity. Patents are necessary because drug development is extremely expensive and has a limited commercial window. GMP manufacturing is essential because a clinical-grade drug must be identical, pure, stable, and contaminant-free; gray-market peptides do not meet this standard. Preclinical models must prove both mechanism and translational plausibility; failure to measure the right endpoint can kill a program even when biology is real. Bimagrumab’s main effect in humans was robust muscle-mass gain and fat-mass loss, but strength improvements were smaller than expected. Combination therapy with GLP-1 agents may be the future of obesity treatment: induce weight loss, preserve lean mass, then maintain remission. Preventive medicine, including cancer prevention, is a major untapped opportunity in drug development. Selective mTORC1 inhibition likely has anti-aging potential, but human proof remains unresolved.
Data Points: Clinical indications reviewed by Novartis team: ~7,000 - Initial unmet-need mapping for the New Indication Discovery Unit Frail nursing-home resident 3-year mortality: approached 90% - Used to illustrate severity of frailty/sarcopenia-related outcomes Fall-study sample size: 60 subjects - Older adults in one living environment followed in the accelerometer study Fall-study follow-up: 6 months - Duration of the nursing-home fall measurement study Captured fall events: 117 events - Falls observed in the nursing-home study Accelerometer fall detection sensitivity: ~17% - Device detected a minority of true falls Accelerometer positive predictive value: ~17% - Only a small fraction of device alerts corresponded to actual falls Rodent muscle mass increase with BEMA: ~20–30%+ - Magnitude of hypertrophy seen in mice Human muscle mass increase with BEMA: ~4–8% - Typical increase observed in humans/older adults Phase-one high dose explored: ~50–100 mg/kg - Approximate upper end of dosing reached in first-in-human development Phase-two effective BEMA dose cited: 10 mg/kg monthly - Dose used in the 48-week type 2 diabetes study Type 2 diabetes outcome: ~0.7–0.8% absolute HbA1c reduction - Observed in diabetics receiving BEMA LDL increase in BELEEVE: ~20% - Adverse effect seen in the obesity/combination study Weight loss in high-dose combination arm: ~22–23% of starting body weight - 72-week outcome with BEMA plus GLP-1 therapy Fat loss in high-dose combination arm: 45.7% of starting body fat - A notable effect comparable to bariatric surgery BELEEVE study size: 507 participants - Large factorial obesity study of BEMA plus semaglutide Investors approached for spinout: 53 - Fundraising for the BEMA-focused company Capital raised for spinout: $70 million - Initial financing for the company that advanced BEMA Desired financing: ~$100 million - What the team would have preferred to raise Estimated small-company next-stage cost: ~$20–30 million - Rough figure discussed for IND-enabling plus phase-one runway One-year skin-cancer recurrence risk in high-risk cohort: ~50% - Rationale for a cancer-prevention trial Cancer-cell-line panel size: 1,000 cell lines - Broad Institute screen for sensitivity to the new cancer-prevention compound
Pivotal Quotes: "We need to make the most needed medicines." — Dr. Lloyd Klickstein: Explaining the mandate behind Novartis's New Indication Discovery Unit "I start with patients and the indications and medical need." — Dr. Lloyd Klickstein: Describing his core framework for drug discovery "I want to help as many people as I can." — Dr. Lloyd Klickstein: Explaining why he prefers larger indications when choosing development programs
Implications: The episode shows that successful drug development is as much about regulatory strategy, endpoints, and manufacturing as biology. It also suggests obesity care is moving toward combination therapy, while prevention-focused medicine and new pathway drugs could reshape future care.
About Peter Attia Drive
Expert insight on health, performance, longevity, critical thinking, and pursuing excellence. Dr. Peter Attia (Stanford/Hopkins/NIH-trained MD) talks with leaders in their fields.